Advanced

Calmidazolium inhibits muscarinic receptor-mediated PLC activation in SH-SY5Y cells

Larsson, Christer LU and Alling, Christer LU (1995) In NeuroReport 6(9). p.1333-1337
Abstract
The aim of this study was to investigate the effect of a calmodulin antagonist, calmidazolium, on the muscarinic receptor-mediated increase in inositol 1,4,5-trisphosphate [I(1,4,5)P3] in SH-SY5Y cells. Exposure to 10 microM calmidazolium suppressed the initial I(1,4,5)P3 peak increase (IC50 1 microM) whereas the steady-state was less affected. Furthermore, calmidazolium displayed non-competitive antagonistic properties of [3H]quinuclidinyl benzylate binding to intact SH-SY5Y cells and to membranes from these cells. These effects were also obtained with another calmodulin inhibitor, trifluoperazine (10 microM). These results demonstrate that novel finding that the calmodulin inhibitors calmidazolium and trifluoperazine act as... (More)
The aim of this study was to investigate the effect of a calmodulin antagonist, calmidazolium, on the muscarinic receptor-mediated increase in inositol 1,4,5-trisphosphate [I(1,4,5)P3] in SH-SY5Y cells. Exposure to 10 microM calmidazolium suppressed the initial I(1,4,5)P3 peak increase (IC50 1 microM) whereas the steady-state was less affected. Furthermore, calmidazolium displayed non-competitive antagonistic properties of [3H]quinuclidinyl benzylate binding to intact SH-SY5Y cells and to membranes from these cells. These effects were also obtained with another calmodulin inhibitor, trifluoperazine (10 microM). These results demonstrate that novel finding that the calmodulin inhibitors calmidazolium and trifluoperazine act as non-competitive muscarinic antagonists in SH-SY5Y cells and inhibit muscarinic receptor-stimulated phospholipase C activation in these cells. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
NeuroReport
volume
6
issue
9
pages
1333 - 1337
publisher
Lippincott Williams & Wilkins
external identifiers
  • pmid:7669998
  • scopus:0029059237
ISSN
1473-558X
language
English
LU publication?
yes
id
52a772d0-fa21-4467-a058-caad72a7ed53 (old id 1108723)
date added to LUP
2008-07-24 15:47:53
date last changed
2017-01-01 05:02:18
@article{52a772d0-fa21-4467-a058-caad72a7ed53,
  abstract     = {The aim of this study was to investigate the effect of a calmodulin antagonist, calmidazolium, on the muscarinic receptor-mediated increase in inositol 1,4,5-trisphosphate [I(1,4,5)P3] in SH-SY5Y cells. Exposure to 10 microM calmidazolium suppressed the initial I(1,4,5)P3 peak increase (IC50 1 microM) whereas the steady-state was less affected. Furthermore, calmidazolium displayed non-competitive antagonistic properties of [3H]quinuclidinyl benzylate binding to intact SH-SY5Y cells and to membranes from these cells. These effects were also obtained with another calmodulin inhibitor, trifluoperazine (10 microM). These results demonstrate that novel finding that the calmodulin inhibitors calmidazolium and trifluoperazine act as non-competitive muscarinic antagonists in SH-SY5Y cells and inhibit muscarinic receptor-stimulated phospholipase C activation in these cells.},
  author       = {Larsson, Christer and Alling, Christer},
  issn         = {1473-558X},
  language     = {eng},
  number       = {9},
  pages        = {1333--1337},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {NeuroReport},
  title        = {Calmidazolium inhibits muscarinic receptor-mediated PLC activation in SH-SY5Y cells},
  volume       = {6},
  year         = {1995},
}